CytomX Therapeutics
CTMX
141 hedge funds and large institutions have $846M invested in CytomX Therapeutics in 2018 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 42 increasing their positions, 43 reducing their positions, and 15 closing their positions.
1,438% more call options, than puts
Call options by funds: $2.72M | Put options by funds: $177K
160% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 15
33% more capital invested
Capital invested by funds: $637M → $846M (+$209M)
18% more funds holding
Funds holding: 119 → 141 (+22)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 43
1.44% less ownership
Funds ownership: 78.49% → 77.05% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$69.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.5M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.5M |
| 4 |
Renaissance Technologies
New York
|
+$7.02M |
| 5 |
PC
PointState Capital
New York
|
+$4.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TG
TRV GP
Boston,
Massachusetts
|
-$65.6M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$23.7M |
| 3 |
PA
Perceptive Advisors
New York
|
-$8.04M |
| 4 |
Millennium Management
New York
|
-$6.92M |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$4.19M |
CTMX Hedge Fund Activity: Q1 2018 in Review
141 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2018, worth a combined $846M — up 33% from $637M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new CTMX positions and 15 closed out — a net gain of 24 holders — while 42 added to existing stakes and 43 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $69.7M. The largest seller was TRV GP, cutting an estimated $65.6M.
- 141 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2018, up from 119 in Q4 2017.
- Funds reported $846M of CytomX Therapeutics stock for Q1 2018, up 33% quarter-over-quarter.
- 39 funds opened new CytomX Therapeutics positions in Q1 2018 and 15 closed out, a net change of +24 holders.
- The largest CytomX Therapeutics buyer in Q1 2018 was T. Rowe Price Associates, an estimated $69.7M added.
- The largest CytomX Therapeutics seller in Q1 2018 was TRV GP, an estimated $65.6M sold.
Based on aggregated 13F filings for Q1 2018.